Skip to content

Krystal Biotech, Inc. KRYS Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax at other companies

Flutter Entertainment logo
Flutter EntertainmentFLUT
$0
VMI
Valmont IndustriesVMI
$0
RenaissanceRe Holdings logo
RenaissanceRe HoldingsRNR
-$1.3M-691%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$176K-32.3%
Ladder Capital logo
Ladder CapitalLADR
$46K-53.5%
Two Harbors Investment Corporation logo
Two Harbors Investment CorporationTWO

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
Krystal Biotech, Inc. (KRYS) reported other comprehensive income unrealized holding gain loss on securities arising during period net of tax of -$1.58M in Q1 2026.
How has Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax changed year-over-year?
Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax decreased by 558.4% year-over-year, from $344K to -$1.58M.
What is the long-term trend for Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
Over 2 years (2021 to 2024), Krystal Biotech, Inc.'s other comprehensive income unrealized holding gain loss on securities arising during period net of tax has grown at a 61.4% compound annual growth rate (CAGR), from -$169K to -$440K.
What does other comprehensive income unrealized holding gain loss on securities arising during period net of tax mean?
The change in value of investments the company still owns but has not yet sold.
How do you interpret other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
An increase signals positive market performance of the company's investment holdings, while a decrease signals market depreciation.
How does other comprehensive income unrealized holding gain loss on securities arising during period net of tax compare across companies?
Common for companies with significant treasury or investment portfolios; varies based on market conditions.